Replimune Group, Inc., headquartered in Woburn, Massachusetts, is an innovative biotechnology company dedicated to advancing oncolytic immunotherapies that transform cancer treatment paradigms. Utilizing its proprietary Immuno-Oncology platform, Replimune uniquely targets tumor cells while enhancing the body's immune response against them, which is reflected in its promising clinical trial results. As a significant player in the dynamic oncology landscape, Replimune is well-positioned for robust growth and is poised to make substantial contributions to the future of cancer therapy. Show more

Location: 500 UNICORN PARK DRIVE, WOBURN, MA, UNITED STATES, 01801, Woburn, MA, 01801, USA | Website: https://www.replimune.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

572.2M

52 Wk Range

$2.68 - $14.80

Previous Close

$6.93

Open

$7.14

Volume

1,725,184

Day Range

$7.12 - $7.80

Enterprise Value

386M

Cash

123M

Avg Qtr Burn

-65.96M

Insider Ownership

2.21%

Institutional Own.

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RP1 + Opdivo (nivolumab) Details Melanoma	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP2 + Opdivo Details Uveal melanoma	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP1 + Opdivo Details Non-melanoma skin cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP2 in comb w/ atezolizumab and bevacizumab Details Hepatocellular carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP1 + Libtayo (cemiplimab) Details Cutaneous squamous cell carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP2 + Durvalumab (Oncolytic Virus) Details Biliary Tract Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP1 Details Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP3 in comb w/std. of care Details Cancer, Head and neck squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP3 +/- Opdivo Details Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details Cancer, Colorectal cancer , Hepatocellular carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.